Cryo-Cell (NYSE: CCEL) CFO exercises options for 7,500 shares at $3.10
Rhea-AI Filing Summary
Cryo-Cell International VP Finance and CFO Jill M. Taymans exercised stock options to acquire 7,500 shares of Common Stock on May 28, 2026 at $3.10 per share. Following this exercise, she directly holds 52,896 Common Stock shares.
She also retains multiple outstanding stock option awards on Common Stock with exercise prices ranging from $3.54 to $8.00 per share and expiration dates between 2027 and 2031, covering several tranches of 7,000 to 20,000 underlying shares each, subject to stated vesting and performance conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 7,500 shares
Net Buy
8 txns
Insider
TAYMANS JILL M
Role
VP Finance, CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 7,500 | $3.10 | $23K |
| Exercise | Common Stock | 7,500 | $3.10 | $23K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
Holdings After Transaction:
Stock Option — 77,000 shares (Direct);
Common Stock — 52,896 shares (Direct)
Footnotes (5)
- F1. Stock options vest 1/5 per year commencing on September 23, 2020.
- F2. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
- F3. Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
- F4. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
- F5. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
